Cell Therapy

FDA Probes Immunotherapies; Biotech Faces Financial and Market Shifts
Research & Development FDA Probes Immunotherapies; Biotech Faces Financial and Market Shifts

The biopharmaceutical industry is in a state of flux, marked by the FDA's scrutiny of immunotherapy drugs, financial challenges faced by biotech startups, and promising advancements in vaccine development and obesity treatments. As regulatory, operational, and market dynamics evolve, companies must

How Will eXmoor's New License Transform Cell and Gene Therapy?
Research & Development How Will eXmoor's New License Transform Cell and Gene Therapy?

The transformative journey of eXmoor Pharma has reached a pivotal moment with the recent acquisition of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This milestone

Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk and Weight Loss
Research & Development Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk and Weight Loss

Eli Lilly's groundbreaking medication, tirzepatide, also known as Mounjaro and Zepbound, has demonstrated remarkable success in reducing the risk of Type 2 diabetes and promoting weight loss. The results from the extensive Phase 3 trial, named SURMOUNT-1, have sparked significant interest and

Grail Cuts 350 Jobs to Focus on Galleri Test and Secure FDA Approval
Research & Development Grail Cuts 350 Jobs to Focus on Galleri Test and Secure FDA Approval

Grail, a leading player in the cancer detection industry, is making a significant cut to its workforce, laying off approximately 350 employees, which represents about 25% of its total workforce. This substantial reduction is part of a major restructuring effort aimed at refocusing the company’s

FDA Approves Tecelra, Pioneering Cell Therapy for Synovial Sarcoma
Research & Development FDA Approves Tecelra, Pioneering Cell Therapy for Synovial Sarcoma

The U.S. Food and Drug Administration (FDA) has ushered in a new era in cancer treatment with the approval of Tecelra (afamitresgene autoleucel), an innovative therapy aimed at combating synovial sarcoma. This rare and aggressive form of cancer predominantly impacts young adults and has

Can BiTEs Revolutionize Autoimmune Disease Treatment Strategies?
Research & Development Can BiTEs Revolutionize Autoimmune Disease Treatment Strategies?

The recent collaboration between biotech creation engines Two River and Third Rock Ventures has led to the formation of TRC 2004, which has licensed a bispecific T-cell engager (BiTE) from Genor Biopharma. TRC 2004 has acquired the ex-China rights to the CD20/CD3-targeting BiTE, known as GB261,

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later